Posted on November 13, 2020

Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s

 

AUTHORS

Takaaki Oba, Mark D. Long, Tibor Keler, Henry C. Marsh, Hans Minderman, Scott I. Abrams, Song Liu & Fumito Ito

 

SUMMARY

The ability of cancer cells to ensure T-cell exclusion from the tumor microenvironment is a significant mechanism of resistance to anti-PD-1/PD-L1 therapy. Evidence indicates crucial roles of Batf3-dependent conventional type-1 dendritic cells (cDC1s) for inducing antitumor T-cell immunity; however, strategies to maximize cDC1 engagement remain elusive. Here, using multiple orthotopic tumor mouse models resistant to anti-PD-L1-therapy, we are testing the hypothesis that in situ induction and activation of tumor-residing cDC1s overcomes poor T-cell infiltration. In situ immunomodulation with Flt3L, radiotherapy, and TLR3/CD40 stimulation induces an influx of stem-like Tcf1+ Slamf6+ CD8+ T cells, triggers regression not only of primary, but also untreated distant tumors, and renders tumors responsive to anti-PD-L1 therapy. Furthermore, serial in situ immunomodulation (ISIM) reshapes repertoires of intratumoral T cells, overcomes acquired resistance to anti-PD-L1 therapy, and establishes tumor-specific immunological memory. These findings provide new insights into cDC1 biology as a critical determinant to overcome mechanisms of intratumoral T-cell exclusion.

REFERENCES

Oba, T., Long, M.D., Keler, T. et al. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nat Commun 11, 5415 (2020). https://doi.org/10.1038/s41467-020-19192-z

PRODUCT HIGHLIGHTS

The following Bio X Cell in vivo monoclonal antibodies were featured in the publication:

The Bio X Cell Singapore website will permanently redirect to https://bioxcell.com/ from 30th April 2026.

This transition is designed to streamline access to new products, product data, technical resources, and provide a smoother ordering experience through our unified global platform.

All products, documentation, and customer support will continue to be available at: https://bioxcell.com/

https://bxcell.sg/ will remain active temporarily to support this transition before redirecting automatically.

Please update your bookmarks to https://bioxcell.com/.

For regional support, please refer to https://bioxcell.com/our-distributors.

For Singapore customers, please contact our authorized distributor, Omnicell Pte Ltd:-

eMail : enquiry@omnicell.com.sg ; Tel : 67470201

Website : www.omnicell.com.sg 

Do not show this again [ CLOSE ]